SPEEDX
10.5.2021 22:02:12 CEST | Business Wire | Press release
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, announced it has been awarded up to US $1.8 million from CARB-X, a global non-profit partnership dedicated to supporting research and development to address the rising threat of drug-resistant bacteria. SpeeDx represents the first Australian-based diagnostics company to receive CARB-X funding and a further $1.9 million will be available once the project reaches defined milestones. Funds will be used to develop a rapid test for the combined detection of Chlamydia trachomatis and Neisseria gonorrhoeae , while identifying antimicrobial resistance (AMR) of gonorrhea infections towards common antibiotic treatments. Chlamydia (CT) and gonorrhea (NG) are globally significant sexually transmitted infections with serious health complications if left untreated,1 and AMR NG is an urgent public health threat.2
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005228/en/
Current antibiotic susceptibility testing methods fail to offer timely and comprehensive susceptibility/resistance information, especially in resource-limited settings. SpeeDx aims to develop an affordable, fast (<60 mins), point-of-care test for the detection of bacteria that cause CT and NG, in addition to determining the susceptibility of NG to three cheap, orally administered, and accessible antibiotics: cefixime, ciprofloxacin, and azithromycin. SpeeDx will utilize their newly patented In Signia™ technology to both assess the presence of active bacterial infection and AMR status. SpeeDx is collaborating with QuantuMDx to port the test onto their Q-POC™ sample to answer qPCR & integrated microarray system - a small battery-powered, simple-to-use device suitable for remote settings.
“We are working closely with QuantuMDx to supply affordable and innovative diagnostics with the goal of significantly improving the standard of care and antibiotic stewardship in STI management,” said Colin Denver, SpeeDx CEO. “This project is an excellent application of our recently developed In Signia technology and the support from CARB-X for this venture will help accelerate this development and extend access in critical need areas.”
Jonathan O’Halloran, Chief Executive, QuantuMDx added: “Antimicrobial resistance is a global public health threat and requires a global response. With rapidly rising rates of AMR, it is no longer good enough to simply provide a pathogen ID, we must also determine what therapeutics the infection is resistant to and which ones the infection are sensitive to. Performing this all within a single assay, as the patient waits, will be transformational. We launch Q-POC™ - our rapid PCR diagnostic system - later this year and we’re looking forward to this, our first commercial collaboration, with SpeeDx.”
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
About CARB-X
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global non-profit partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria. CARB-X is led by Boston University
and funding is provided by the Biomedical Advanced Research and Development Authority (BARDA),
part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the US Department of Health and Human Services, the Wellcome Trust
, a global charity based in the UK working to improve health globally, Germany’s Federal Ministry of Education and Research (BMBF),
the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF)
, the Bill & Melinda Gates Foundation
, and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID)
, part of the US National Institutes of Health (NIH). CARB-X is investing up to $480 million from 2016-2022 to support innovative antibiotics and other therapeutics, vaccines, and rapid diagnostics. CARB-X supports the world’s largest and most innovative pipeline of preclinical products against drug-resistant infections. CARB-X is headquartered at Boston University School of Law. carb-x.org/
. Follow us on Twitter @CARB_X.
About QuantuMDx
QuantuMDx Group is an ambitious company with a global vision of empowering the world to control and eradicate disease by making transformative, quality point-of-care diagnostic technologies universally accessible. QuantuMDx has operations and strategic partnerships in the United States, Asia, Australasia, Europe and Africa – keeping it at the forefront of molecular diagnostics. For more information go to: www.quantumdx.com
References
- WHO, News Release: More than 1 million new curable sexually transmitted infections every day, 6 June 2016
- WHO, News Release: Antibiotic-resistant gonorrhoea on the rise, new drugs needed, 7 July 2017
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005228/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-severe Atopic Dermatitis16.3.2026 11:53:00 CET | Press release
Almirall announces positive, top-line results from Phase 3 ADorable-1 trialADorable-1 met co-primary efficacy endpoints, with 63% of paediatric patients achieving meaningful skin improvement (EASI-75) and 44% reaching clear or almost clear skin (IGA 0,1) at week 16.Key secondary endpoints showed significant itch relief (Pruritus NRS ≥4 point improvement), reduced overall disease severity (EASI-90) and improved quality of life (CDLQI ≥6-Point Improvement) in children and adolescents with moderate-to-severe atopic dermatitis treated with lebrikizumab.Skin conditions can have a profound physical and emotional impact on people’s lives1, and Atopic Dermatitis (AD) peaks in childhood – with around 60% of cases appearing within the first year of life2. Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line results from the pivotal Phase 3 ADorable-1 trial evaluating efficacy and safety of lebrikizumab for children and adoles
Experian Marks a Breakthrough in Consumer AI with the Next Evolution of Its Virtual Assistant16.3.2026 11:00:00 CET | Press release
Smarter, more adaptive assistant advances personalized, conversational financial guidance powered by trusted data Experian today unveiled the next evolution of the Experian Virtual Assistant, EVA™, a significant advancement in its Consumer First AI strategy that expands personalized, conversational financial guidance to millions of consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316538160/en/ Experian today unveiled the next evolution of the Experian Virtual Assistant, EVA™. “This next generation of EVA reflects the direction of our consumer AI strategy,” said Debbie Hsu, Executive Vice President of Product, Experian Consumer Services. “We are bringing together conversational AI, personalization, and our trusted data foundation to deliver guidance that is intuitive, relevant, and actionable. Our focus is on helping consumers make smarter financial decisions in ways that feel simple and empowering.” Built to scal
Triton Partners Successfully Closes Fund 6 at €5.5 Billion Target16.3.2026 08:00:00 CET | Press release
Triton Partners today announces the successful close of its sixth flagship mid-market fund (“T6” or “the Fund”) on target at €5.5 billion, the largest fund to date for Triton. The Fund has raised capital from new and existing investors globally, underscoring the continued confidence of Limited Partners in Triton’s European mid-market strategy and the Firm’s ability to build better businesses. Triton’s Mid-Market buyout (TMM) strategy focuses on its core sectors of industrial technology, business services and healthcare. As a responsible owner of choice, T6 will invest where its market and investment insights provide an edge, positioning the firm to capitalise on attractive opportunities, supported by the Accelerator Unit, Europe’s largest value creation team. T6 seeks to maintain the strong performance of previous funds, all having achieved top quartile returns. Reflecting this consistent track record, Triton was recently named as one of three European managers in the HEC global univer
Syngenta deepens research capabilities with QuantumBasel partnership16.3.2026 08:00:00 CET | Press release
At the World Agri-Tech Innovation Summit, Syngenta, a global leader in agricultural innovation, today announced it is exploring how quantum computing can help farmers meet the growing demands of food production in a changing climate. The company has partnered with QuantumBasel, Switzerland's first commercial quantum computing hub, to apply quantum technologies to agricultural research and development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316646014/en/ Ion trap, which uses electromagnetic fields to confine and control ions for use as quantum bits (qubits). Farmers worldwide face mounting pressure to produce more food sustainably amid unpredictable weather and evolving pest and disease challenges. Meeting these demands requires new scientific approaches that go beyond what classical computing can deliver, particularly when it comes to understanding the complex molecular and biological systems that underpin crop sc
NTT DATA Launches GCC Innovation Acceleration Program to Support Innovation Creation by Global Companies16.3.2026 04:30:00 CET | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced the launch of its GCC Innovation Acceleration Program. This is designed to support global companies rapidly establishing and scaling their strategic offshore hubs in India, including Global Capability Centers (GCC) and other innovation and delivery hubs. Launched in October 2025, the program aims to support more than 50 companies over the next three years. The demand for highly skilled IT personnel has expanded globally, and as a result, companies are increasingly using overseas bases to meet innovation needs. NTT DATA identified India as a stand-out market to launch the GCC Innovation Acceleration Program because of its abundance of talent and strong technical capabilities. India’s Global Capability Center ecosystem, delivering IT services and back-office functions to multinationals, is poised for strong growth of nearly 70%, targeting $110 billion in 2030 from the current $65 billion, according
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom